2015 Compounding Drug Development 
Putting Patients First Blog
JUNE 26, 2025
At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. A first priority is clarifying how providers should submit claims for drugs subject to the MFP.
BioPharma Dive
AUGUST 8, 2025
But in the ensuing years, AstraZeneca learned more about the subset of people who did respond to its medication, and by 2015 Iressa was re-approved based on studies in patients with these “EGFR mutations.” The lung cancer treatment Iressa, which targeted the mutation of the EGFR gene, was cleared by U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 16, 2022
According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 In 2015, Alzheimer’s Therapeutics International found there was an estimated 46.8 percent, and driven largely by collaboration of existing players, reach $6.8
pharmaphorum
MARCH 24, 2022
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine.
pharmaphorum
OCTOBER 31, 2022
The small-molecule PIKfyve inhibitor – called VRG50635 – has been administered to the first subject in the phase 1 trial involving healthy volunteers, according to the San Francisco-based biotech, which was founded in 2015 by Alice Zhang and Jason Chen.
pharmaphorum
AUGUST 17, 2022
Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in milestone payments and tiered royalties when all is said and done. Additional payments will be tied to specific research, development, and sales milestones.
European Pharmaceutical Review
DECEMBER 21, 2022
Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. In 2015 he joined the Process Chemistry & Catalysis group at F. PNAS 2022, Vol.
Expert insights. Personalized for you.
Let's personalize your content